A growing body of preclinical work in animals and in vitro, is examining ivermectin and fenbendazole — two inexpensive, widely used veterinary antiparasitcs — as potential anticancer agents in animals. The core finding is striking: these antiparasitic agents hit cancer cells hard while leaving normal cells largely intact, while currently used chemotherapy agents like taxanes, hit not just the cancer cells but they also destroy healthy cells.